234 related articles for article (PubMed ID: 37212600)
1. Effect of Torsemide Versus Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial.
Greene SJ; Velazquez EJ; Anstrom KJ; Clare RM; DeWald TA; Psotka MA; Ambrosy AP; Stevens GR; Rommel JJ; Alexy T; Ketema F; Kim DY; Desvigne-Nickens P; Pitt B; Eisenstein EL; Mentz RJ;
Circulation; 2023 Jul; 148(2):124-134. PubMed ID: 37212600
[TBL] [Abstract][Full Text] [Related]
2. Torsemide vs Furosemide Among Patients With New-Onset vs Worsening Chronic Heart Failure: A Substudy of the TRANSFORM-HF Randomized Clinical Trial.
Krim SR; Anand S; Greene SJ; Chen A; Wojdyla D; Vilaro J; Haught H; Herre JM; Eisenstein EL; Anstrom KJ; Pitt B; Velazquez EJ; Mentz RJ
JAMA Cardiol; 2024 Feb; 9(2):182-188. PubMed ID: 37955908
[TBL] [Abstract][Full Text] [Related]
3. Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial.
Mentz RJ; Anstrom KJ; Eisenstein EL; Sapp S; Greene SJ; Morgan S; Testani JM; Harrington AH; Sachdev V; Ketema F; Kim DY; Desvigne-Nickens P; Pitt B; Velazquez EJ;
JAMA; 2023 Jan; 329(3):214-223. PubMed ID: 36648467
[TBL] [Abstract][Full Text] [Related]
4. Torsemide Versus Furosemide After Discharge in Patients Hospitalized With Heart Failure Across the Spectrum of Ejection Fraction: Findings From TRANSFORM-HF.
Kapelios CJ; Greene SJ; Mentz RJ; Ikeaba U; Wojdyla D; Anstrom KJ; Eisenstein EL; Pitt B; Velazquez EJ; Fang JC;
Circ Heart Fail; 2024 Mar; 17(3):e011246. PubMed ID: 38436075
[TBL] [Abstract][Full Text] [Related]
5. Impact of baseline kidney dysfunction on oral diuretic efficacy following hospitalization for heart failure - insights from TRANSFORM-HF.
Martens P; Greene SJ; Mentz RJ; Li S; Wojdyla D; Kapelios CJ; Mullens W; Hall ME; Ketema F; Kim DY; Eisenstein EL; Anstrom K; Fang JC; Pitt B; Velazquez EJ; Tang WHW
Eur J Heart Fail; 2024 May; 26(5):1242-1250. PubMed ID: 38558520
[TBL] [Abstract][Full Text] [Related]
6. Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials.
Nassif ME; Windsor SL; Gosch K; Borlaug BA; Husain M; Inzucchi SE; Kitzman DW; McGuire DK; Pitt B; Scirica BM; Shah SJ; Umpierrez G; Austin BA; Lamba S; Khumri T; Sharma K; Kosiborod MN
Circ Heart Fail; 2023 Jul; 16(7):e009837. PubMed ID: 37203441
[TBL] [Abstract][Full Text] [Related]
7. On-treatment analysis of torsemide versus furosemide for patients hospitalized for heart failure: A post-hoc analysis of TRANSFORM-HF.
Kittipibul V; Mentz RJ; Clare RM; Wojdyla DM; Anstrom KJ; Eisenstein EL; Ambrosy AP; Goyal P; Skopicki HA; Ketema F; Kim DY; Desvigne-Nickens P; Pitt B; Velazquez EJ; Greene SJ
Eur J Heart Fail; 2024 May; ():. PubMed ID: 38745502
[TBL] [Abstract][Full Text] [Related]
8. Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial.
Kosiborod MN; Verma S; Borlaug BA; Butler J; Davies MJ; Jon Jensen T; Rasmussen S; Erlang Marstrand P; Petrie MC; Shah SJ; Ito H; Schou M; Melenovský V; Abhayaratna W; Kitzman DW;
Circulation; 2024 Jan; 149(3):204-216. PubMed ID: 37952180
[TBL] [Abstract][Full Text] [Related]
9. Pragmatic Design of Randomized Clinical Trials for Heart Failure: Rationale and Design of the TRANSFORM-HF Trial.
Greene SJ; Velazquez EJ; Anstrom KJ; Eisenstein EL; Sapp S; Morgan S; Harding T; Sachdev V; Ketema F; Kim DY; Desvigne-Nickens P; Pitt B; Mentz RJ;
JACC Heart Fail; 2021 May; 9(5):325-335. PubMed ID: 33714745
[TBL] [Abstract][Full Text] [Related]
10. Comparative Effect of Loop Diuretic Prescription on Mortality and Heart Failure Readmission.
Virkud AV; Chang PP; Funk MJ; Kshirsagar AV; Edwards JK; Pate V; Kosorok MR; Gower EW
Am J Cardiol; 2024 Jan; 210():208-216. PubMed ID: 37972425
[TBL] [Abstract][Full Text] [Related]
11. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial.
Kosiborod MN; Jhund PS; Docherty KF; Diez M; Petrie MC; Verma S; Nicolau JC; Merkely B; Kitakaze M; DeMets DL; Inzucchi SE; Køber L; Martinez FA; Ponikowski P; Sabatine MS; Solomon SD; Bengtsson O; Lindholm D; Niklasson A; Sjöstrand M; Langkilde AM; McMurray JJV
Circulation; 2020 Jan; 141(2):90-99. PubMed ID: 31736335
[TBL] [Abstract][Full Text] [Related]
12. Torsemide versus furosemide and intermediate-term outcomes in patients with heart failure: an updated meta-analysis.
Miles JA; Hanumanthu BK; Patel K; Chen M; Siegel RM; Kokkinidis DG
J Cardiovasc Med (Hagerstown); 2019 Jun; 20(6):379-388. PubMed ID: 30950982
[TBL] [Abstract][Full Text] [Related]
13. Effect of Furosemide Versus Torsemide on Hospitalizations and Mortality in Patients With Heart Failure: A Meta-Analysis of Randomized Controlled Trials.
Singh S; Goel S; Duhan S; Chaudhary R; Garg A; Tantry US; Gurbel PA
Am J Cardiol; 2023 Nov; 206():42-48. PubMed ID: 37677884
[TBL] [Abstract][Full Text] [Related]
14. Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials.
McMurray JJV; Docherty KF; de Boer RA; Hammarstedt A; Kitzman DW; Kosiborod MN; Maria Langkilde A; Reicher B; Senni M; Shah SJ; Wilderäng U; Verma S; Solomon SD
Circulation; 2024 Mar; 149(11):825-838. PubMed ID: 38059368
[TBL] [Abstract][Full Text] [Related]
15. Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial.
Butler J; Filippatos G; Jamal Siddiqi T; Brueckmann M; Böhm M; Chopra VK; Pedro Ferreira J; Januzzi JL; Kaul S; Piña IL; Ponikowski P; Shah SJ; Senni M; Vedin O; Verma S; Peil B; Pocock SJ; Zannad F; Packer M; Anker SD
Circulation; 2022 Jan; 145(3):184-193. PubMed ID: 34779658
[TBL] [Abstract][Full Text] [Related]
16. Torsemide versus furosemide after acute decompensated heart failure: a retrospective observational study.
Rahhal A; Saad MO; Tawengi K; Assi AAR; Habra M; Ahmed D
BMC Cardiovasc Disord; 2019 May; 19(1):127. PubMed ID: 31138146
[TBL] [Abstract][Full Text] [Related]
17. Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial.
Kosiborod MN; Angermann CE; Collins SP; Teerlink JR; Ponikowski P; Biegus J; Comin-Colet J; Ferreira JP; Mentz RJ; Nassif ME; Psotka MA; Tromp J; Brueckmann M; Blatchford JP; Salsali A; Voors AA
Circulation; 2022 Jul; 146(4):279-288. PubMed ID: 35377706
[TBL] [Abstract][Full Text] [Related]
18. Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial).
Mentz RJ; Hasselblad V; DeVore AD; Metra M; Voors AA; Armstrong PW; Ezekowitz JA; Tang WH; Schulte PJ; Anstrom KJ; Hernandez AF; Velazquez EJ; O'Connor CM
Am J Cardiol; 2016 Feb; 117(3):404-11. PubMed ID: 26704029
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of torasemide versus furosemide in symptomatic therapy in heart failure patients: Preliminary results from the randomized TORNADO trial.
Balsam P; Ozierański K; Marchel M; Gawałko M; Niedziela Ł; Tymińska A; Sieradzki B; Sieradzki M; Fojt A; Bakuła E; Główczyńska R; Peller M; Markulis M; Bednarski J; Kowalik R; Cacko A; Niewiński G; Filipiak KJ; Opolski G; Grabowski M
Cardiol J; 2019; 26(6):661-668. PubMed ID: 31909470
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive review of the loop diuretics: should furosemide be first line?
Wargo KA; Banta WM
Ann Pharmacother; 2009 Nov; 43(11):1836-47. PubMed ID: 19843838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
